Preclinical models are developed to test lead compounds for toxicity and efficacy. They are valuable tools for minimizing development costs and reducing failures prior to the commencement of human trials. Problems with traditional animal models such as cost, ethics and suitability have prompted researchers to develop new models and systems to overcome these disadvantages.
Scope of this research
- Assessment of current developments in preclinical ADMET research for drug discovery and development.
- Evaluation of the drivers behind innovation in preclinical research.
- Details of current trends in ADMET research and how technology companies are developing models to improve and accelerate discovery and development.
- Analysis of the in-vivo, in-vitro, in-silico and systems biology models that are advancing toxicity prediction in early drug discovery.
- Key recommendations for industry players relating to the development of preclinical models to accelerate productivity and increase knowledge.
Research and analysis highlights
Established preclinical models correlate poorly with human in-vivo biological responses, and innovation is therefore needed to approximate human responses more accurately.
In-vivo, in-vitro and in-silico models are becoming increasingly more sophisticated, and a push for integration is creating demand for highly efficient centralized platforms to expedite predictive ADMET insight.
Pharmaceutical companies need more innovative preclinical solutions to advance drug discovery efforts, and in-silico biosimulation has the potential to transform the discovery and development process.
Key reasons to purchase this research
- Understand the basis of ADMET testing and why it is a necessary and important component of preclinical research.
- Evaluate the key recent developments and activities of companies who are developing and licensing new ADMET technologies.
- Identify existing models and discover how new ones are being developed to improve productivity and knowledge.
- Assess the technologies and systems that are driving drug discovery and development.
- Examine action points and considerations for technology providers and pharmaceutical companies looking to accelerate preclinical research.